Eye opening study by @ekoermann & colleagues @nyulangone As @EricTopol says, this was not anticipated. nature.com/articles/s41591-0… This thread by @AdamRodmanMD is extremely helpful for providing context: x.com/adamrodmanmd/status/20…

🗞️🚨‼️Post-hoc analysis on #ExtrahepaticCCA and #GallbladderCancer treated with 1L CisGem in the ABC01/02/03 trials now published at @JHEP_Reports 🤩 🆕NEW DATA - jhep-reports.eu/article/S258… 🤓PRIOR iCCA paper - academic.oup.com/jnci/articl… @TheChristieNHS @OfficialUoM @MGMcNamara

Yes, yes and yes, ‘nuff said @curecc @CcaEns @OHSUKnight

Adjuvant hepatic arterial infusion pump CTx with floxuridine for resectable CRC metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial. #ASCO26 👉mPFS 15 vs 15.5 mo 👉similar 5-yr OS rate 🧐no benefit for HAIP... @myesmo @ASCO

Adjuvant HAIP resectable #CRCLM with low CRS #ASCO26 ➡️n=110 resection pump v 108pts resection alone ❎no ⬆️in mPFS 15.0 v 16.0 mths ➡️hepatic PFS 37.6 v 21.8mths 90 day postop mortality 4pts v 1pt No role in this setting but feasible @ASCO @OncoAlert Imp study & 👏🏻presentation

Take a listen. 👇🏼👇🏼

Postoperative Hepatic Arterial Infusion with Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial. Co-authored by @GelliMaximilia1. Read the full article. bit.ly/4dgTW0Q

Original Article: Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer nej.md/4f7xfhX Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer nej.md/4neOTCE #Oncology #Gastroenterology

📊 Research Summary: Among patients with multiorgan metastatic #ColorectalCancer, tumor debulking combined with systemic chemotherapy failed to provide a survival benefit over chemotherapy alone and resulted in higher rates of serious adverse events. ja.ma/4eCnHv8

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma @Cancer_Cell @curecc @KRASKickers #KRAS cell.com/cancer-cell/fulltex…

#AACR26☝🏽A question that’s lingered for years: dMMR/MSI-H➡️immunotherapy… but can we induce it? Can pMMR/MSS tumors be converted➡️dMMR/MSI-H—and made responsive to IO? Remarkably, this team has done it.✅ 🤯 🎯 NP1867 🔆🔅 @CD_AACR @OncoAlert @AACR aacrjournals.org/cancerdisco…

Cholangiocarcinoma 2026: status quo, unmet needs and priorities nature.com/articles/s41575-0… #liverpath

This 2-hour Stanford lecture breaks down how models like ChatGPT and Claude are actually built, clearer than what many people in top AI roles ever get exposed to. Save this and set aside two hours today. It might end up being the most valuable thing you learn all week.

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

New drugs take aim at one of cancer’s deadliest mutations “You can actually re-educate the cell: ‘hey, this is disposable, just remove it’” nature.com/articles/d41586-0…

IPMN 🫧 and adjuvant chemotherapy: current evidence 🍇 1.3k InvasiveIPMN / 60% had adjuvant chemo 💉 70% had contemporary regimens 😢 NO survival benefit (median 70 months) 👉 Controlled data on specific IPMN type urgently needed! 🧐 @JAMANetworkOpen jamanetwork.com/journals/jam…

What is future for #PDAC❓PAXG, KRAS, FFX @OHSUKnight @PanCAN @SocSurgOnc

Prismatic loupes use deflected optics to get better magnified view of the field while keeping a neutral head/neck posture 👉🏻 ⬇️ flexion, ⬇️ strain, ⬆️ ergonomics vs traditional loupes 🙌 Tried them at #SSO2026 & can’t wait to get my pair and report back on the experience 👀

TRANSPLANT BENEFIT IN CRLM: OUR PAPER, NOW WITH EDITORIAL INSIGHT Honoured to see our paper in Liver Transplantation, accompanied by an editorial emphasising its importance and practical implications [1]. Our study [2] provides the first real-world external validation of the TransMet trial criteria for unresectable colorectal liver metastases, demonstrating that the survival benefit observed in the trial is reproducible outside the trial setting and quantifying the transplant advantage in a clinically meaningful manner. The editorial emphasises several key points raised by our work: the importance of external validation, the need for refined biological selection, the implications for allocation policy, and the significance of multidisciplinary referral and decision-making in this evolving field. I am grateful to all co-authors and collaborators for their valuable contributions to this significant step forward in transplant oncology. [1]journals.lww.com/lt/fulltext… [2]journals.lww.com/lt/fulltext… #LiverTransplantation #TransplantOncology #CRLM #TransMet #LiverTransplant #ColorectalLiverMetastases #SurgicalOncology #Research

Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events. Full phase 2–3 ZSAB-neoGOLP trial results and Research Summary: nejm.org/doi/full/10.1056/NE…